KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Accumulated Expenses: 2020-2024

Historic Other Accumulated Expenses for Royalty Pharma (RPRX) over the last 4 years, with Dec 2024 value amounting to $68.6 million.

  • Royalty Pharma's Other Accumulated Expenses fell 90.00% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 90.00%. This contributed to the annual value of $68.6 million for FY2024, which is 503.08% up from last year.
  • Per Royalty Pharma's latest filing, its Other Accumulated Expenses stood at $68.6 million for FY2024, which was up 503.08% from $11.4 million recorded in FY2023.
  • Over the past 5 years, Royalty Pharma's Other Accumulated Expenses peaked at $68.6 million during FY2024, and registered a low of $11.4 million during FY2023.
  • In the last 3 years, Royalty Pharma's Other Accumulated Expenses had a median value of $12.4 million in 2022 and averaged $30.8 million.
  • Per our database at Business Quant, Royalty Pharma's Other Accumulated Expenses dropped by 8.27% in 2023 and then skyrocketed by 503.08% in 2024.
  • Royalty Pharma's Other Accumulated Expenses (Yearly) stood at $18.6 million in 2020, then reached $12.4 million in 2022, then dropped by 8.27% to $11.4 million in 2023, then skyrocketed by 503.08% to $68.6 million in 2024.